CLL
From the Journals
CAR T-cell therapy neurotoxicity linked to NfL elevations
Even prior to CAR T-cell therapy, patients developing related neurotoxic complications show elevated markers of neuronal injury.
From the Journals
‘Molecular map’ of CLL yields fresh genetic insights
New analysis that refines understanding of two subtypes could lead to better prognoses.
News
First drug therapy approved for childhood GVHD
FDA greenlights ibrutinib for child blood cancer patients with chronic graft-versus-host disease.
Feature
Young children with leukemia are outliving teens
Two new studies spotlight age disparities that continue to plague blood cancer care.
From the Journals
Where women’s voices still get heard less
Only about one-third of board review lectures are presented by women oncologists, and early-career disparities also persist.
From the Journals
Phase 3 data: Zanubrutinib bests standard CLL treatment
Results could spur FDA approval as frontline therapy.
Conference Coverage
Many die waiting for `last-chance’ therapy
Blood cancer patients, especially those with myeloma, face hospice and death while awaiting CAR T-cell therapy.
Feature
Life and death decisions: What keeps oncologists up at night
“It’s part of the discomfort you live with as a patient and oncologist, and when I leave the clinic, that’s one thing that follows me home.”
Feature
CAR T-cell therapy turns 10 and finally earns the word ‘cure’
“We have a couple dozen patients who are 5, 6, 7, 9 years out or more without further therapy. That feels like a cure to me.”
From the Journals
Heed cardiac risk of BTKis for CLL
New consensus statement warns about cardiac risk of using BTKis, but a cardio-oncologist specialist questions its conclusions.
Feature
Drug shortages plague hematology, but preparedness helps
The plight of desperate patients is getting attention – and some remedies.